Skip to content

Whole Body Vibration - a New Therapeutic Approach to Improve Muscle Function in CF

Cystic Fibrosis: Improvement of Muscle Force and Function by Whole Body Vibration Exercise

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00388466
Enrollment
10
Registered
2006-10-16
Start date
2005-06-30
Completion date
2006-08-31
Last updated
2006-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystic Fibrosis

Keywords

whole body vibration, muscle function, cystic fibrosis, mechanography, chair-rising-test

Brief summary

The purpose of this study is to evaluate the effects of whole body vibration (WBV) on muscle function in adult CF-patients.

Detailed description

Cystic Fibrosis (CF) is the most common chronic hereditary disease in Caucasians. Due to improved therapy and better understanding of the disease, life expectancy has risen to an average of 38 years and is continuing to rise. With the increased life-expectancy it becomes even more important to maintain functional activity as part of quality of life. Mechanical stimulation in form of whole body vibration (WBV) is a new type of exercise currently tested in sports, geriatrics and rehabilitation. It has recently been found to be a safe and efficient method to activate muscular activity via stretch reflexes leading to improvement of muscular performance, body balance and physical functioning. 10 patients of the CF Center Cologne, Germany, took part in the Galileo study. They were provided by the vibrating platform (Galileo 2000)for whole body vibration training at home. The patients were standing in an upright position receiving vertical vibration of frequencies between 20-25 Hz. This vibration exercise evokes muscle contractions via stretch reflexes improving muscular activity. The training schedule consisted of three 3-minute sessions twice a day 5 days per week for 3 months. Every 4 weeks the patients were seen for assessment of muscle function to evaluate the effects of this new intervention.

Interventions

DEVICEGALILEO

Sponsors

University of Cologne
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* clinical diagnosis of Cystic Fibrosis * age older than 18 years

Exclusion criteria

* hypersplenic syndrome * acute arthritis or osteomyelitis

Design outcomes

Primary

MeasureTime frame
muscle force at the beginning of the study and after 3 months
muscle power at the beginning of the study and after 3 months

Secondary

MeasureTime frame
pulmonary function testing at the beginning of the study and after 3 months

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026